Leukemia: all 5,475 studies

Page 10 of 55. Open to participants first (629), then studies with results posted, then the rest; newest registration first within each.

• A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)CompletedNCT02632721Phase 1/2Results posted
• Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/LymphomaCompletedNCT02631746Phase 2Results posted
• A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid LeukemiaTerminatedNCT02627677Phase 3Results posted
• Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDSCompletedNCT02626715Phase 2Results posted
• Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AMLCompletedNCT02626338Phase 1/2Results posted
• A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML PatientsTerminatedNCT02614560Phase 1/2Results posted
• A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)CompletedNCT02614066Phase 1/2Results posted
• Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic LeukemiaTerminatedNCT02612311Phase 3Results posted
• An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)CompletedNCT02610777Phase 2Results posted
• Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD ProphylaxisCompletedNCT02593123Phase 2Results posted
• A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)CompletedNCT02588651Phase 2Results posted
• Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)TerminatedNCT02588092Phase 1Results posted
• Reduced Intensity Conditioning Transplant Using Haploidentical DonorsCompletedNCT02581007Phase 2Results posted
• An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 MutationCompletedNCT02577406Phase 3Results posted
• Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02566304Phase 2Results posted
• Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AMLCompletedNCT02560025Phase 2Results posted
• Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLLTerminatedNCT02557516Phase 1/2Results posted
• Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft MalignanciesCompletedNCT02556931Phase 2Results posted
• High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute LeukemiaCompletedNCT02551718Not applicableResults posted
• Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT02547662Phase 2Results posted
• A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)TerminatedNCT02545283Phase 3Results posted
• A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02538965Phase 2Results posted
• Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic LeukemiaTerminatedNCT02538614Phase 1Results posted
• Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young AdultsTerminatedNCT02535806Phase 2Results posted
• Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)TerminatedNCT02535364Phase 2Results posted
• A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)CompletedNCT02533401Phase 2Results posted
• Nivolumab in AML in Remission at High Risk for RelapseCompletedNCT02532231Phase 2Results posted
• Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AMLTerminatedNCT02532010Phase 2Results posted
• Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic LeukemiaStatus unknownNCT02530619Not applicableResults posted
• Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic LeukemiaCompletedNCT02530515Phase 2Results posted
• Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid LeukemiaCompletedNCT02530476Phase 1/2Results posted
• Alvocidib Biomarker-driven Phase 2 AML StudyTerminatedNCT02520011Phase 2Results posted
• Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or LymphomaTerminatedNCT02518750Phase 2Results posted
• 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02509546Phase 1/2Results posted
• IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk LeukemiaTerminatedNCT02508324Phase 2Results posted
• Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical DonorCompletedNCT02500550Phase 2Results posted
• A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDSCompletedNCT02488408Phase 1/2Results posted
• Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic LeukemiaCompletedNCT02484430Phase 2Results posted
• CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic SarcomaCompletedNCT02484391Phase 1Results posted
• Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) PatientsCompletedNCT02481297Phase 2Results posted
• Yoga to Alleviate Fatigue, Anxiety and Pain in Adolescents During Treatment for Lymphoma or LeukemiaTerminatedNCT02473523Not applicableResults posted
• An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive ChemotherapyCompletedNCT02472145Phase 2/3Results posted
• Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of DosesCompletedNCT02467270Phase 2Results posted
• Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)CompletedNCT02464657Phase 1/2Results posted
• Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell TransplantationCompletedNCT02458235Phase 2Results posted
• Vaccinating Children After ChemotherapyCompletedNCT02447718Phase 4Results posted
• Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)CompletedNCT02441803Phase 2Results posted
• A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid TumorsTerminatedNCT02440685Phase 1/2Results posted
• Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute LeukemiaCompletedNCT02440178Phase 2Results posted
• Study of Efficacy and Safety of CTL019 in Pediatric ALL PatientsCompletedNCT02435849Phase 2Results posted
• CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or LymphomaCompletedNCT02424968Phase 2Results posted
• Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter TransformationCompletedNCT02420912Phase 2Results posted
• An Open-label Phase II Study of Lorvotuzumab MertansineCompletedNCT02420873Phase 2Results posted
• Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic LeukemiaTerminatedNCT02420717Phase 2Results posted
• Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic MalignanciesTerminatedNCT02419755Phase 2Results posted
• Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaTerminatedNCT02419469Phase 2Results posted
• Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02416908Phase 1/2Results posted
• Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaCompletedNCT02412306Phase 1/2Results posted
• Use Feasibility of the iThermonitor in Pediatrics Patients on Myelosuppresive TherapiesCompletedNCT02410252Not applicableResults posted
• A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT02406742Phase 1/2Results posted
• Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)TerminatedNCT02404220Phase 1/2Results posted
• Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia PatientsCompletedNCT02400281Phase 1/2Results posted
• Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia PatientsCompletedNCT02400255Phase 2Results posted
• Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaTerminatedNCT02399917Phase 2Results posted
• Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02397720Phase 2Results posted
• Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT02396134Phase 2Results posted
• MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML PatientsCompletedNCT02395822Phase 2Results posted
• Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual DiseaseTerminatedNCT02370888Phase 1Results posted
• HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or LymphomaCompletedNCT02370160Phase 1/2Results posted
• A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With AsparaginaseCompletedNCT02369653Phase 3Results posted
• A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML PatientsCompletedNCT02367456Phase 1Results posted
• Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCLTerminatedNCT02361346Phase 1/2Results posted
• Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell TransplantationCompletedNCT02356159Phase 1/2Results posted
• Stem Cell Monitoring for CML Patients Undergoing Nilotinib TherapyCompletedNCT02353728Phase 2Results posted
• Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02353143Phase 1Results posted
• Study of Ibrutinib in Subjects With Acute Myeloid LeukemiaTerminatedNCT02351037Phase 2Results posted
• Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCTTerminatedNCT02349178Phase 2Results posted
• SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission InductionCompletedNCT02348489Phase 3Results posted
• Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)TerminatedNCT02343939Phase 1/2Results posted
• Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65TerminatedNCT02341495Phase 2Results posted
• Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic LeukemiaCompletedNCT02340780Phase 2Results posted
• Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLLCompletedNCT02337829Phase 2Results posted
• Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02337478Phase 2Results posted
• Treatment for Executive Dysfunction in Adult Survivors of Childhood Acute Lymphoblastic LeukemiaCompletedNCT02336282Not applicableResults posted
• Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid LeukemiaCompletedNCT02328755Phase 1/2Results posted
• Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic MalignanciesCompletedNCT02323867Not applicableResults posted
• Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)TerminatedNCT02323113Phase 1/2Results posted
• A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)CompletedNCT02320487Phase 2Results posted
• Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)TerminatedNCT02319369Phase 1Results posted
• Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CMLCompletedNCT02311998Phase 1/2Results posted
• Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell LymphocytosisTerminatedNCT02309515Phase 2Results posted
• An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT02305563Phase 1/2Results posted
• Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedNCT02303821Phase 1Results posted
• Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin LymphomaCompletedNCT02303392Phase 1Results posted
• Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in RemissionTerminatedNCT02302846Phase 2Results posted
• Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)CompletedNCT02301156Phase 3Results posted
• Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromesCompletedNCT02296242Phase 1/2Results posted
• Phase 1 Study of SGI-110 in Patients With Acute Myeloid LeukemiaCompletedNCT02293993Phase 1Results posted
• A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous LeukemiaCompletedNCT02287233Phase 1/2Results posted
• A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic PhaseCompletedNCT02272777Phase 3Results posted

← Leukemia overview